|
Fig. S5
WT embryos treated with cytoskeleton altering agents.
A. Phalloidin labeling of F-actin at 16-cell stage for WT, WT treated with DMSO, WT treated with 1µg/mL cytochalasinD, and WT treated with 3µg/mL cytochalasinD from activation.
B. Bright field images of WT in vitro fertilized embryos in egg water, DMSO, 5µg/mL cytochalasinD, 10µg/mL cytochalasinD, and 15µg/mL cytochalasinD from activation at 50mpf.
C. gsc transcripts revealed by WISH in WT embryos treated at 1 hpf with DMSO, 3µg/mL cytochalasinD, 0.01µg/mL nocodazole, and 5µM taxol at 8 hpf; dorsal view.
D. ntl and gsc transcripts revealed by WISH in WT embryos treated at 1 hpf with DMSO, 0.002µg/mL nocodazole, and 0.005µg/mL nocodazole; 6 hpf animal pole view.